AdvaMed is hopeful the Trump administration will propose a new reimbursement pathway by year's end that could supply temporary, automatic coverage to US FDA-designated breakthrough devices on the condition of data collection. That is among the issues discussed by AdvaMed Chairman and CVRx Inc. President and CEO Nadim Yared in a interview with Medtech Insight's editor David Filmore at the 2018 MedTech Conference in Philadelphia. Check out the interview in the video below.
AdvaMed Chair Nadim Yared Talks Challenges, Priorities
The AdvaMed chairman and CVRx CEO spoke to Medtech Insight from the floor of the Pennsylvania Convention Center at this year's MedTech Conference. The discussion focused on the industry's push for a breakthrough reimbursement pathway, the impact of US-China tariff wars and the industry's answer to challenges from grassroots patient groups on device safety, among other challenges and priorities.
More from Regulation
More from Policy & Regulation
• By
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
• By
Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.
• By
Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.